Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 3
1976 4
1977 14
1978 9
1979 11
1980 5
1981 4
1982 4
1983 7
1985 4
1986 6
1987 1
1988 1
1989 1
1991 4
1993 1
1995 1
1996 1
1997 4
1998 6
1999 7
2000 3
2001 1
2002 2
2003 6
2004 1
2006 1
2007 2
2008 1
2009 2
2010 5
2011 6
2012 10
2013 12
2014 13
2015 9
2016 11
2017 6
2018 5
2019 2
2020 4
2021 5
2022 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, Paiva B, Bahlis NJ, Plesner T, Hungria V, Moreau P, Mateos MV, Perrot A, Iida S, Facon T, Kumar S, van de Donk NWCJ, Sonneveld P, Spencer A, Krevvata M, Heuck C, Wang J, Ukropec J, Kobos R, Sun S, Qi M, Munshi N. Cavo M, et al. Among authors: heuck c. Blood. 2022 Feb 10;139(6):835-844. doi: 10.1182/blood.2021011101. Blood. 2022. PMID: 34289038 Free PMC article. Clinical Trial.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ. San-Miguel J, et al. Among authors: heuck c. Blood. 2022 Jan 27;139(4):492-501. doi: 10.1182/blood.2020010439. Blood. 2022. PMID: 34269818 Free PMC article. Clinical Trial.
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis N, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Clemens PL, Masterson T, Lantz K, O'Rourke L, Heuck C, Qin X, Parasrampuria DA, Yuan Z, Xu S, Qi M, Usmani SZ. Mateos MV, et al. Among authors: heuck c. Lancet Haematol. 2020 May;7(5):e370-e380. doi: 10.1016/S2352-3026(20)30070-3. Epub 2020 Mar 23. Lancet Haematol. 2020. PMID: 32213342 Clinical Trial.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Usmani SZ, et al. Among authors: heuck c. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459. Haematologica. 2022. PMID: 35354247 Free PMC article. Clinical Trial.
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. Rodriguez-Otero P, et al. Among authors: heuck c. Blood Cancer J. 2024 Feb 2;14(1):24. doi: 10.1038/s41408-023-00966-9. Blood Cancer J. 2024. PMID: 38307865 Free PMC article. Review.
Proteasome inhibitors: introduction.
Heuck CJ, Shaughnessy JD Jr. Heuck CJ, et al. Semin Hematol. 2012 Jul;49(3):193-5. doi: 10.1053/j.seminhematol.2012.05.001. Semin Hematol. 2012. PMID: 22726541 No abstract available.
Proteasome inhibitors and bone disease.
Qiang YW, Heuck CJ, Shaughnessy JD Jr, Barlogie B, Epstein J. Qiang YW, et al. Among authors: heuck cj. Semin Hematol. 2012 Jul;49(3):243-8. doi: 10.1053/j.seminhematol.2012.04.011. Semin Hematol. 2012. PMID: 22726547 Free PMC article. Review.
Mechanism of action of lenalidomide in hematological malignancies.
Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A. Kotla V, et al. Among authors: heuck c. J Hematol Oncol. 2009 Aug 12;2:36. doi: 10.1186/1756-8722-2-36. J Hematol Oncol. 2009. PMID: 19674465 Free PMC article. Review.
Reply.
Wolthers OD, Heuck C. Wolthers OD, et al. Among authors: heuck c. J Pediatr. 1999 Aug;135(2 Pt 1):265-6. doi: 10.1016/s0022-3476(99)70037-5. J Pediatr. 1999. PMID: 10431127 No abstract available.
197 results